Contribution: Industrial Research Assistance Program – Contributions to Firms
Exciton Technologies Inc.
$194,000.00
Advancement of silver-oxygen scaffold gel production for anti-infective wound care
FY 2021-22 · 2021-07-01
Summary
Recent global events have shed light on the vulnerabilities within our health care systems. The growing threat of antimicrobial resistance is hailed as a pandemic in the making. As the antibiotics drug development pipeline dwindles, effective solutions to combat antimicrobial resistant strains of pathogenic bacteria are urgently needed. ETI has successfully developed a silver-oxygen scaffold gel device for the effective eradication of biofilm and pathogenic bacterium, including resistant clinical isolates, while facilitating wound healing. Employing a multidisciplinary team, this project will facilitate large scale production and distribution of this disruptive device to capture market share and combat resistance.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
861842136
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2022-07-31
Agreement Number
974259
Agreement Start Date
2021-07-01
Agreement Title
Advancement of silver-oxygen scaffold gel production for anti-infective wound care
Agreement Title (French)
Progrès dans la production de gel à base d'argent et d'oxygène pour le traitement anti-infectieux de plaies
Agreement Type
Contribution
Agreement Value
$194,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Recent global events have shed light on the vulnerabilities within our health care systems. The growing threat of antimicrobial resistance is hailed as a pandemic in the making. As the antibiotics drug development pipeline dwindles, effective solutions to combat antimicrobial resistant strains of pathogenic bacteria are urgently needed. ETI has successfully developed a silver-oxygen scaffold gel device for the effective eradication of biofilm and pathogenic bacterium, including resistant clinical isolates, while facilitating wound healing. Employing a multidisciplinary team, this project will facilitate large scale production and distribution of this disruptive device to capture market share and combat resistance.
Description (French)
De récents événements mondiaux ont mis en lumière les failles de nos systèmes de soins de santé. La menace croissante de la résistance aux antimicrobiens est présentée comme une pandémie en devenir. Alors que le flux de développement de médicaments antibiotiques s'amenuise, il est urgent de trouver des solutions efficaces pour combattre les souches de bactéries pathogènes résistantes aux antimicrobiens. L'ETI a mis au point avec succès un dispositif de gel à base d'argent et d'oxygène pour éradiquer efficacement le biofilm et les bactéries pathogènes, y compris les isolats cliniques résistants, tout en facilitant la cicatrisation des plaies. Grâce à une équipe multidisciplinaire, ce projet facilitera la production et la distribution à grande échelle de ce dispositif révolutionnaire, et ce, afin de conquérir des parts de marché et de combattre la résistance.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
861842136
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Exciton Technologies Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2021-2022-Q1-974259
